Etodolac

Nonsteroidal Anti-inflammatory Drug — MUSCULO-SKELETAL SYSTEM

Key facts

Etodolac is an ofp drug in the Nonsteroidal Anti-inflammatory Drug class catalogued in DrugCentral. It was first approved by the FDA in 1991. Its mechanism of action is classified as Cyclooxygenase Inhibitors. DrugCentral lists 2 molecular targets, including PTGS2 and PTGS1. Recorded indications include Juvenile rheumatoid arthritis, Osteoarthritis, Pain and Rheumatoid arthritis.

• Approval status: ofp (first approved 1991 by the FDA).
• Drug class: Nonsteroidal Anti-inflammatory Drug.
• Mechanism of action: Cyclooxygenase Inhibitors.
• Molecular targets: PTGS2 and PTGS1 (2 listed in DrugCentral).
• Indications: Juvenile rheumatoid arthritis, Osteoarthritis, Pain and Rheumatoid arthritis.
• ATC code: M01AB08 (Acetic acid derivatives and related substances).
• Molecular formula: C17H21NO3; molecular weight 287.36 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (4)

• Juvenile rheumatoid arthritis
• Osteoarthritis
• Pain
• Rheumatoid arthritis

Off-label uses (4)

• Ankylosing spondylitis
• Bursitis
• Gout
• Tendinitis

Contraindications (14)

• Blood coagulation disorder
• Cardiovascular event risk
• Chronic heart failure
• Coronary artery bypass graft
• Disease of liver
• Disorder of cardiovascular system
• Gastrointestinal hemorrhage
• Gastrointestinal ulcer
• Hypertensive disorder
• Kidney disease
• Myocardial infarction
• Peptic ulcer
• Pregnancy, function
• Smokes tobacco daily

Mechanism & targets

• Mechanism of action (MoA): Cyclooxygenase Inhibitors
• Established pharmacologic class: Nonsteroidal Anti-inflammatory Drug

Molecular targets (2)

Target	Gene	Action	Activity
Prostaglandin G/H synthase 2	PTGS2	inhibitor	IC50 5.70
Prostaglandin G/H synthase 1	PTGS1	unknown	IC50 5.58

Regulatory approvals (1)

Date	Agency	Marketed as	Applicant	Orphan
1991-01-31	FDA	—	WYETH PHARMS INC

ATC classification

ATC code	Therapeutic hierarchy
M01AB08	MUSCULO-SKELETAL SYSTEM › ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS › ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS › Acetic acid derivatives and related substances

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Drug hypersensitivity	69.7
Interstitial lung disease	62.3
Off label use	49.2
Gastric haemorrhage	45.9
Gastrointestinal haemorrhage	39.0
Gastric ulcer	38.4
Duodenal ulcer	31.0
Hepatic function abnormal	28.3
Mydriasis	22.5
Infusion related reaction	21.3
Wound	20.7
Injection site erythema	20.0

Chemical structure

Full physicochemical, ADMET and 3D-structure analysis of Etodolac is on its molecule page.

• Molecular formula: C₁₇H₂₁NO₃
• Molecular weight: 287.36 g/mol
• CAS number: 41340-25-4
• InChIKey: NNYBQONXHNTVIJ-UHFFFAOYSA-N
• PubChem CID: 3308

CCC1=CC=CC2=C1NC1=C2CCOC1(CC)CC(O)=O

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Etodolac used for?

DrugCentral lists the following indications for Etodolac: Juvenile rheumatoid arthritis, Osteoarthritis, Pain and Rheumatoid arthritis.

How does Etodolac work?

Etodolac is classified as Cyclooxygenase Inhibitors; its molecular targets in DrugCentral include PTGS2 (inhibitor) and PTGS1.

When was Etodolac first approved?

Etodolac was first approved by the FDA in 1991.

What drug class does Etodolac belong to?

Etodolac is in the Nonsteroidal Anti-inflammatory Drug class.

What is the chemical formula of Etodolac?

Etodolac has the molecular formula C17H21NO3 and a molecular weight of 287.36 g/mol.

Sources

• DrugCentral drug card 1103 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL622 — compound record and bioactivity
• PubChem CID 3308 — chemical identifiers
• DrugBank DB00749 — drug record
• FDA UNII 2M36281008 — substance identity
• DailyMed: FDA labels for Etodolac — current prescribing information (label search)
• UniProt P35354 (PTGS2) — target protein
• UniProt P23219 (PTGS1) — target protein
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral

How this page is built: methodology · editorial policy & corrections.